IBDEI0K9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8936,2)
 ;;=^5008704
 ;;^UTILITY(U,$J,358.3,8937,0)
 ;;=N12.^^69^608^7
 ;;^UTILITY(U,$J,358.3,8937,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8937,1,3,0)
 ;;=3^Tubulo-Interstitial Nephritis
 ;;^UTILITY(U,$J,358.3,8937,1,4,0)
 ;;=4^N12.
 ;;^UTILITY(U,$J,358.3,8937,2)
 ;;=^5015575
 ;;^UTILITY(U,$J,358.3,8938,0)
 ;;=L97.509^^69^608^4
 ;;^UTILITY(U,$J,358.3,8938,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8938,1,3,0)
 ;;=3^Non-Pressure Chr Ulcer Unspec Foot w/ Unspec Severity
 ;;^UTILITY(U,$J,358.3,8938,1,4,0)
 ;;=4^L97.509
 ;;^UTILITY(U,$J,358.3,8938,2)
 ;;=^5009544
 ;;^UTILITY(U,$J,358.3,8939,0)
 ;;=M86.10^^69^608^5
 ;;^UTILITY(U,$J,358.3,8939,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8939,1,3,0)
 ;;=3^Osteomylitis,Acute,Unspec Site
 ;;^UTILITY(U,$J,358.3,8939,1,4,0)
 ;;=4^M86.10
 ;;^UTILITY(U,$J,358.3,8939,2)
 ;;=^5014521
 ;;^UTILITY(U,$J,358.3,8940,0)
 ;;=E85.9^^69^609^1
 ;;^UTILITY(U,$J,358.3,8940,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8940,1,3,0)
 ;;=3^Amyloidosis,Unspec
 ;;^UTILITY(U,$J,358.3,8940,1,4,0)
 ;;=4^E85.9
 ;;^UTILITY(U,$J,358.3,8940,2)
 ;;=^334185
 ;;^UTILITY(U,$J,358.3,8941,0)
 ;;=N00.9^^69^609^3
 ;;^UTILITY(U,$J,358.3,8941,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8941,1,3,0)
 ;;=3^Nephritic Syndrome w/ Morphologic Changes,Acute
 ;;^UTILITY(U,$J,358.3,8941,1,4,0)
 ;;=4^N00.9
 ;;^UTILITY(U,$J,358.3,8941,2)
 ;;=^5015500
 ;;^UTILITY(U,$J,358.3,8942,0)
 ;;=N08.^^69^609^2
 ;;^UTILITY(U,$J,358.3,8942,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8942,1,3,0)
 ;;=3^Glomerular Disorders in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,8942,1,4,0)
 ;;=4^N08.
 ;;^UTILITY(U,$J,358.3,8942,2)
 ;;=^5015569
 ;;^UTILITY(U,$J,358.3,8943,0)
 ;;=N03.9^^69^609^4
 ;;^UTILITY(U,$J,358.3,8943,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8943,1,3,0)
 ;;=3^Nephritic Syndrome w/ Morphologic Changes,Chronic
 ;;^UTILITY(U,$J,358.3,8943,1,4,0)
 ;;=4^N03.9
 ;;^UTILITY(U,$J,358.3,8943,2)
 ;;=^5015530
 ;;^UTILITY(U,$J,358.3,8944,0)
 ;;=N05.8^^69^610^1
 ;;^UTILITY(U,$J,358.3,8944,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8944,1,3,0)
 ;;=3^Nephritic Syndrome w/ Morphologic Changes,Unspec
 ;;^UTILITY(U,$J,358.3,8944,1,4,0)
 ;;=4^N05.8
 ;;^UTILITY(U,$J,358.3,8944,2)
 ;;=^5134085
 ;;^UTILITY(U,$J,358.3,8945,0)
 ;;=M30.0^^69^611^2
 ;;^UTILITY(U,$J,358.3,8945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8945,1,3,0)
 ;;=3^Polyarteritis Nodosa
 ;;^UTILITY(U,$J,358.3,8945,1,4,0)
 ;;=4^M30.0
 ;;^UTILITY(U,$J,358.3,8945,2)
 ;;=^5011738
 ;;^UTILITY(U,$J,358.3,8946,0)
 ;;=N04.9^^69^611^1
 ;;^UTILITY(U,$J,358.3,8946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8946,1,3,0)
 ;;=3^Nephrotic Syndrome w/ Morphologic Changes
 ;;^UTILITY(U,$J,358.3,8946,1,4,0)
 ;;=4^N04.9
 ;;^UTILITY(U,$J,358.3,8946,2)
 ;;=^5015540
 ;;^UTILITY(U,$J,358.3,8947,0)
 ;;=N13.30^^69^612^2
 ;;^UTILITY(U,$J,358.3,8947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8947,1,3,0)
 ;;=3^Hydronephrosis,Unspec
 ;;^UTILITY(U,$J,358.3,8947,1,4,0)
 ;;=4^N13.30
 ;;^UTILITY(U,$J,358.3,8947,2)
 ;;=^5015578
 ;;^UTILITY(U,$J,358.3,8948,0)
 ;;=N13.9^^69^612^12
 ;;^UTILITY(U,$J,358.3,8948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8948,1,3,0)
 ;;=3^Uropathy,Obstructive & Reflux,Unspec
 ;;^UTILITY(U,$J,358.3,8948,1,4,0)
 ;;=4^N13.9
 ;;^UTILITY(U,$J,358.3,8948,2)
 ;;=^5015589
 ;;^UTILITY(U,$J,358.3,8949,0)
 ;;=N40.1^^69^612^1
